Table 2

Cetuximab for advanced colorectal cancer
Author, year Pat. [n] Treatment regimen Median PFS [months] Median OS [months]
+ cet - cet + cet - cet
Tabernero, 2007 [29] 43 FOLFOX/cetuximab 12.3 - 30.5 -
Borner, 2008 [30] 74 CAPOX/cetuximab 7.2 5.8 20.5 16.5
Arnold, 2008 [31] 49 FUFOX/cetuximab 8.1 - 28.2 -
Cartwright, 2008 [32] 70 CAPIRI/cetuximab 8.1 - 20.5 -
Van Cutsem, 2009 [33] 348* FOLFIRI/cetuximab 9.9* 8.7* 24.9* 21*
Bokemeyer, 2009 [34] 134* FOLFOX/cetuximab 7.7* 7.2* - -
Tol, 2009 [35] 755 CAPOX/bev/cet 9.4 10.7 19.4 20.3
Maughan, 2011 [36] 729* FOLFOX/CAPOX/cet 8.6* 8.6* 17.0* 17.9*
Tveit, 2012 [37] 566 FLOX/cetuximab 8.3 7.9 19.7 20.4

*wild-type KRAS.

Glockzin et al.

Glockzin et al. BMC Cancer 2013 13:67   doi:10.1186/1471-2407-13-67

Open Data